Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2016Circulation

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

View Full Paper
Ask AI
Bookmark
Share

Authors

Hiddo J.L. HeerspinkHiddo J.L. HeerspinkPreventive CardiologyBPBruce A. PerkinsSinai Health SystemDFDavid FitchettGeneral / Preventive / Lipids

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Heerspink et al. (2016) studied this question.

synapsesocial.com/papers/69deac02077ec87fd1e93e65https://doi.org/10.1161/circulationaha.116.021887
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon increases energy expenditure independently of brown adipose tissue activation in humans2015 · 165 citations
  2. 2Influence of Weight Reduction on Blood Pressure2003 · 1,403 citations
  3. 3Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension2015 · 85 citations
  4. 4Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial2016 · 909 citations
  5. 5Energy balance and metabolic changes with sodium‐glucose co‐transporter 2 inhibition2015 · 117 citations